Your one point of contact for Actelion services and support
PATHwatch™ - Online Patient Management Tool
PAH Pathways Interactive Resource Locator
PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more ยป
Gain instant, secure access to patient information with registration
Fast, secure, and useful information about your patients on pulmonary arterial hypertension (PAH) therapy—on demand. PAH Pathways makes it easy.
With PATHwatch. our online patient management tool, you can save time and paperwork, gaining instant and important information about your patients who are either enrolled in the Tracleer Access Program (T.A.P.®) or are taking Ventavis:
Access in-depth status reports 24 hours a day: Quickly access patient profiles, including T.A.P. and Ventavis enrollment dates, shipment history, insurance information, and patient status.
Monitor shipments: Get updates on recent shipments to patients, notes from distributors on pending patients, and archives of past shipments.
Identify groups of patients easily: Search for patients or groups of patients by enrollment date and name of insurance.
Register today and start saving time and paperwork:
Call toll-free 1-866-ACTELION (228-3546) or download our PATHwatch User Registration form and fax to : 1-866-279-0669. Your username and password will arrive via secure overnight delivery.
Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class II-IV symptoms, to improve exercise ability and decrease the rate of clinical worsening. Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these potential benefits are sufficient to offset the risk of liver injury in WHO Class II patients, which may preclude future use as their disease progresses.
Tracleer Important Safety Information
Because of the associated risks, Tracleer may be prescribed only through the Tracleer Access Program. Potential for serious liver injury (including, after prolonged treatment, rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) – Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High potential for major birth defects – Pregnancy must be excluded and prevented through the use of reliable forms of birth control; monthly pregnancy tests should be obtained.
Contraindicated for use with cyclosporine A and glyburide.
Please see full Prescribing Information, including BOXED WARNING and Medication Guide.
Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
Important safety information about Ventavis:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.
Please see full Prescribing Information